Filtered By:
Condition: Hypertension
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 587 results found since Jan 2013.
'Exciting' siRNA Therapy for Hypertension Passes First Hurdle
(MedPage Today) -- Patients with hypertension successfully dialed down their angiotensinogen levels and had lasting reductions in blood pressure (BP) following one injection of an investigational small interfering RNA (siRNA) therapy, according...
Source: MedPage Today Cardiovascular - July 19, 2023 Category: Cardiology Source Type: news
GSE214742 CRISPR and siRNA manipulation of SOX17 in human pulmonary artery endothelial cells HPAEC
Contributors : Christopher J Rhodes ; Rachel Walters ; Jurjan AmanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensHPAEC were treated with either siRNA to SOX17 or CRISPR activating or inhibiting the promoter or an enhancer region associated with pulmonary hypertension and sequenced.
Source: GEO: Gene Expression Omnibus - July 10, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Contribution of TRPC channels in human and experimental pulmonary arterial hypertension
Am J Physiol Lung Cell Mol Physiol. 2023 Jun 27. doi: 10.1152/ajplung.00011.2023. Online ahead of print.ABSTRACTPulmonary arterial hypertension (PAH) is due to progressive distal pulmonary artery (PA) obstruction leading to right ventricular hypertrophy and failure. Exacerbated store-operated Ca2+ entry (SOCE) contributes to PAH pathogenesis, mediating human PA smooth muscle cells (hPASMCs) abnormalities. The transient receptor potential canonical channels (TRPC family) are Ca2+-permeable channels contributing to SOCE in different cell types, including PASMCs. However, the properties, signaling pathways, and contribution t...
Source: American Journal of Physiology. Lung Cellular and Molecular Physiology - June 27, 2023 Category: Cytology Authors: Bastien Masson Ana ïs Saint-Martin Willer Mary Dutheil Lucille Penalva H élène Le Ribeuz Kristelle El Jekmek Yann Ruchon Sylvia Cohen-Kaminsky Jessica Sabourin Marc Humbert Olaf Mercier David Montani V éronique Capuano Fabrice Antigny Source Type: research
Ginsenoside Rg1 ameliorates hypoxia-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition and inflammation by regulating CCN1
Biomed Pharmacother. 2023 May 20;164:114920. doi: 10.1016/j.biopha.2023.114920. Online ahead of print.ABSTRACTPulmonary arterial hypertension (PAH) is a chronic obstructive disease characterized by vascular remodeling. Studies have confirmed that ginsenoside Rg1 can improve pulmonary hypertension to a certain extent, but the potential mechanism by which it improves hypoxia-induced PAH remains unclear. The aim of this study was to investigate the therapeutic effect of ginsenoside Rg1 on hypoxia-induced PAH. The results showed that hypoxia promoted inflammation, EndMT, and vascular remodeling, which were accompanied by decre...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - May 22, 2023 Category: Drugs & Pharmacology Authors: Bai-Lin Tang Yu Liu Jing-Liang Zhang Mei-Li Lu Hong-Xin Wang Source Type: research
